HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Bibliographic Details
Main Authors: D.S. Siegel, K. Weisel, A. Zahlten-Kumeli, R. Medhekar, S. Sapra, B. Ding, X. Leleu
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920307227
id doaj-6394fd0540d742f9832c0c81dbb8141c
record_format Article
spelling doaj-6394fd0540d742f9832c0c81dbb8141c2020-11-25T04:05:59ZengElsevierHematology, Transfusion and Cell Therapy2531-13792020-11-0142260HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMAD.S. Siegel0K. Weisel1A. Zahlten-Kumeli2R. Medhekar3S. Sapra4B. Ding5X. Leleu6John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United StatesDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyAmgen Inc., Thousand Oaks, United StatesAmgen Inc., Thousand Oaks, United StatesAmgen Inc., Thousand Oaks, United StatesAmgen Inc., Thousand Oaks, United StatesHôpital Claude Huriez, Lille, Francehttp://www.sciencedirect.com/science/article/pii/S2531137920307227
collection DOAJ
language English
format Article
sources DOAJ
author D.S. Siegel
K. Weisel
A. Zahlten-Kumeli
R. Medhekar
S. Sapra
B. Ding
X. Leleu
spellingShingle D.S. Siegel
K. Weisel
A. Zahlten-Kumeli
R. Medhekar
S. Sapra
B. Ding
X. Leleu
HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Hematology, Transfusion and Cell Therapy
author_facet D.S. Siegel
K. Weisel
A. Zahlten-Kumeli
R. Medhekar
S. Sapra
B. Ding
X. Leleu
author_sort D.S. Siegel
title HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
title_short HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
title_full HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
title_fullStr HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
title_full_unstemmed HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
title_sort health-related quality of life outcomes from the phase 3 candor study comparing carfilzomib, dexamethasone, and daratumumab to carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
publisher Elsevier
series Hematology, Transfusion and Cell Therapy
issn 2531-1379
publishDate 2020-11-01
url http://www.sciencedirect.com/science/article/pii/S2531137920307227
work_keys_str_mv AT dssiegel healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
AT kweisel healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
AT azahltenkumeli healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
AT rmedhekar healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
AT ssapra healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
AT bding healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
AT xleleu healthrelatedqualityoflifeoutcomesfromthephase3candorstudycomparingcarfilzomibdexamethasoneanddaratumumabtocarfilzomibanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma
_version_ 1724433061667405824

Similar Items